Navigation Links
An ITG Majestic Market Research Study Indicates a Bright Future for Gilenya, Despite Concerns About Its Safety
Date:12/17/2010

NEW YORK, Dec. 17, 2010 /PRNewswire-FirstCall/ -- A study published this week by ITG (NYSE: ITG) revealed that Novartis recently approved drug, Gilenya, has already taken share from market leaders in the multiple sclerosis (MS) market, and uptake is expected to increase significantly over the next year.  Gilenya came onto the market in late September as the first FDA-approved oral disease-modifying MS drug, and Novartis initially faced safety concerns and monitoring requirements that deterred some physicians from adopting the new drug.  Over 60% of neurologists in ITG's study cited safety concerns and monitoring as limiting their use of the drug, but most indicated that their prescribing of Gilenya will increase significantly over the course of 2011 as they continue to shift inadequate responders from other MS therapies to the new drug.  Early switching data from ITG's proprietary panel of neurologists indicates that BIIB's Avonex may be the biggest loser of all, as nearly one-third of switches to Gilenya thus far have been from Avonex.

The study titled Event Pulse: Launch of Gilenya shows that Gilenya has been detailed heavily to neurologists since its launch.  Neurologists in the study reported more frequent details on Gilenya in November than any of the other MS therapies.  Study findings reveal that Novartis reps seem to be promoting the drug's unique oral formulation and its efficacy compared to market leaders, especially Biogen Idec's Avonex. Still, results from the study show that Novartis has not been able to completely allay neurologists' concerns about Gilenya's safety. Until resolved, Gilenya will likely be prescribed primarily for patients who have discontinued or have had an inadequate response to other MS therapie
'/>"/>

SOURCE ITG
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
2. FDA Advisory Committees Recommend Continued U.S. Marketing Authorization for Trasylol(R)
3. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
4. ADVENTRX Announces Completion of Patient Enrollment in ANX-530 Marketing-Enabling Clinical Study
5. Results of TRIUMPH-1 Trial of Viveta in Pulmonary Arterial Hypertension to Be Announced Before Market Open on Thursday, November 1, 2007
6. Inverness Medical Innovations to Present at CIBC World Markets 18th Annual Healthcare Conference on November 7, 2007
7. ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
8. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
9. Replidyne to Participate on Anti-infective Panel at RBC Capital Markets Healthcare Conference
10. GE Healthcare and Novavax Establish Collaboration To Develop and Market Pandemic Influenza Solution
11. Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... July 29, 2015  Unilife Corporation ("Unilife" or the ... developer, manufacturer and supplier of injectable drug delivery systems, ... that provides the Company with flexibility and control to ... has signed an equity purchase agreement for up to ... a Chicago -based institutional investor, which ...
(Date:7/29/2015)... 2015  Nektar Therapeutics (Nasdaq: NKTR ) will announce ... 2015 on Wednesday, August 5, 2015, after the close of ... executive officer, will host a conference call to review the ... Time (PT). The press release and a ... through a link that is posted on the home page ...
(Date:7/29/2015)... Calif. , July 29, 2015 Daiichi ... Daiichi Sankyo Group, announced today that The New ... results demonstrating that the investigational drug, PLX3397, an oral ... patients with tenosynovial giant cell tumor (TGCT), a rare, ... Following phase 1 dose-escalation, which evaluated the ...
Breaking Medicine Technology:Unilife Announces Multifaceted Financing Strategy 2Unilife Announces Multifaceted Financing Strategy 3Unilife Announces Multifaceted Financing Strategy 4Unilife Announces Multifaceted Financing Strategy 5Nektar to Announce Financial Results for the Second Quarter 2015 on Wednesday, August 5, 2015, After Close of U.S.-Based Financial Markets 2Nektar to Announce Financial Results for the Second Quarter 2015 on Wednesday, August 5, 2015, After Close of U.S.-Based Financial Markets 3Daiichi Sankyo and Plexxikon Announce Study Published in NEJM Demonstrates PLX3397 Induced Prolonged Tumor Regression in Tenosynovial Giant Cell Tumor (TGCT) in Most Patients 2Daiichi Sankyo and Plexxikon Announce Study Published in NEJM Demonstrates PLX3397 Induced Prolonged Tumor Regression in Tenosynovial Giant Cell Tumor (TGCT) in Most Patients 3Daiichi Sankyo and Plexxikon Announce Study Published in NEJM Demonstrates PLX3397 Induced Prolonged Tumor Regression in Tenosynovial Giant Cell Tumor (TGCT) in Most Patients 4Daiichi Sankyo and Plexxikon Announce Study Published in NEJM Demonstrates PLX3397 Induced Prolonged Tumor Regression in Tenosynovial Giant Cell Tumor (TGCT) in Most Patients 5
(Date:7/30/2015)... ... 30, 2015 , ... Zaca Life has created Recovery Chewable ... water needed, the refreshing berry-flavored tablets are the perfect travel companion. , “We ... that may help with body detoxification, protection and hydration,” said Mark Aleks, Zaca ...
(Date:7/30/2015)... ... July 30, 2015 , ... The American Telemedicine Association (ATA) ... Tradeshow focused exclusively on telemedicine, telehealth and mHealth. The meeting, expected to attract ... take place May 14-17, 2016 in Minneapolis, MN. , ATA’s annual meeting attracts ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... Orange, Riverside, Los Angeles, and San Bernardino counties, today announced that Dr. Michael ... Care Administrator. Dr. Demoratz is a strong proponent of early access to palliative ...
(Date:7/30/2015)... ... 2015 , ... The Beryl Institute announces its sixth annual ... Patient Experience Institute, these offerings reinforce the commitment to help frame and expand ... the experience movement, and provide information and research to support expanded focus and ...
(Date:7/30/2015)... ... July 30, 2015 , ... The Mesothelioma Applied Research ... Patient Registry Act of 2015’. The bill was introduced in Congress yesterday by ... Betty McCollum (D-MN), Joe Kennedy (D-MA), and Leonard Lance (R-NJ). The purpose of ...
Breaking Medicine News(10 mins):Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 2Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 3Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 4Health News:Presentation Proposals for ATA 2016 are Now Being Accepted Online at ATA2016.com 2Health News:Presentation Proposals for ATA 2016 are Now Being Accepted Online at ATA2016.com 3Health News:24/7 Care At Home Welcomes Michael Demoratz, PhD, LCSW, CCM as New Palliative Care Administrator 2Health News:24/7 Care At Home Welcomes Michael Demoratz, PhD, LCSW, CCM as New Palliative Care Administrator 3Health News:The Beryl Institute Opens Applications for 2015 Patient Experience Grant and Scholar Programs 2Health News:The Beryl Institute Opens Applications for 2015 Patient Experience Grant and Scholar Programs 3Health News:Bill to Create Patient Registry for Deadly Cancer Introduced in Congress 2
... Mesa Laboratories, Inc. (Nasdaq: MLAB ), a supplier ... applications, today announced the appointment of Dr. John J. Sullivan ... R. Schmieder, who has been the CEO since founding the ... and resigning his positions of CEO and Treasurer, but will ...
... Corporation (Nasdaq: IRIX ) today reported its financial ... January 3, 2009.Revenues for the fourth quarter of 2008 were ... for the fourth quarter of 2007. The company,s net ... the fourth quarter of 2008 compared with a loss of ...
... , Loss of thinking power is a fear ... in a budding industry for brain training products exercises ... which in 2007 generated $80 million in the United States ... participants must complete a series of daily exercises such as ...
... Washington University School of Medicine in St. Louis have ... damage in humans with no signs of mental impairment. ... study participants with lower levels of a substance known ... fluid (CSF) had reduced whole brain volumes, suggesting that ...
... for others involved in tumor development , , TUESDAY, March 10 ... much lower risk of developing pancreatic cancer, a finding that ... , The study, by researchers at the Dana-Farber ... blood type and the disease, which is diagnosed in about ...
... that permits precise tuning of a gene,s expression in a ... of the gene,s role in normal and abnormal cellular function. ... negative feedback loop in the synthetic gene circuit, a concept ... by scientists at The University of Texas M. D. Anderson ...
Cached Medicine News:Health News:Mesa Labs Announces the Appointment of New CEO 2Health News:Mesa Labs Announces the Appointment of New CEO 3Health News:IRIDEX Reports Fourth Quarter and Full Year 2008 Financial Results 2Health News:IRIDEX Reports Fourth Quarter and Full Year 2008 Financial Results 3Health News:IRIDEX Reports Fourth Quarter and Full Year 2008 Financial Results 4Health News:IRIDEX Reports Fourth Quarter and Full Year 2008 Financial Results 5Health News:IRIDEX Reports Fourth Quarter and Full Year 2008 Financial Results 6Health News:IRIDEX Reports Fourth Quarter and Full Year 2008 Financial Results 7Health News:IRIDEX Reports Fourth Quarter and Full Year 2008 Financial Results 8Health News:Can mental training games help prevent Alzheimer's? 2Health News:Brain damage found in cognitively normal people with Alzheimer's marker 2Health News:Brain damage found in cognitively normal people with Alzheimer's marker 3Health News:Study Links Blood Type and Pancreatic Cancer 2Health News:Synthetic gene circuit allows precise dosing of gene expression 2Health News:Synthetic gene circuit allows precise dosing of gene expression 3
MBP's extra long 200 L pipet tip will reach the bottom of large tubes and vials, preventing your pipettor from contacting the sample container....
... is an immunometric ('sandwich') EIA for ... human serum or plasma. LH in ... monoclonal anti-LH antibodies directed at different ... magnetic particles and the other is ...
... is an HPLC system designed to provide ... levels and aid in the comprehensive identification ... results for glycemic control., ,The A1c assay ... with the accuracy of boronate affinity columns. ...
... of the fastest blood gas ... care situations on the market. ... lung function testing. The ... quick and reliable assessment of ...
Medicine Products: